Literature DB >> 28923231

Future Clinical Trials: Genetically Driven Trials.

Igor Astsaturov1.   

Abstract

The design of modern oncology clinical trials seeks to match patients' cancer molecular biomarkers with medications that specifically target those biomarkers, a general paradigm shift in cancer care coined clinical cancer biology. This approach exploits the synthetic lethality between a specific genetic alteration in the cancer cell and a drug: rapid termination of exaggerated kinase activity exemplifies this phenomenon. Synthetic lethality-based investigations are driven by rapidly evolving technologies for cancer molecular profiling. As these technologies evolve, future clinical trials will test drugs' activity based on the molecular mechanisms rather than by the tumor's appearance under a microscope.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Basket clinical trial; Biomarker; Molecular profiling

Mesh：

Substances：

Year:  2017        PMID： 28923231      PMCID： PMC5645064          DOI： 10.1016/j.soc.2017.05.014

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN： 1055-3207            Impact factor:   3.495


  39 in total

1.  Cancer: mixing cocktails.

Authors:  Charles L Sawyers
Journal:  Nature       Date:  2007-10-25       Impact factor: 49.962

2.  NCI-MATCH launch highlights new trial design in precision-medicine era.

Authors:  Caroline McNeil
Journal:  J Natl Cancer Inst       Date:  2015-07-03       Impact factor: 13.506

3.  Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.

Authors:  Geraldine O'Sullivan Coyne; Naoko Takebe; Alice P Chen
Journal:  Curr Probl Cancer       Date:  2017-02-11       Impact factor: 3.187

4.  Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial.

Authors:  L Belin; M Kamal; C Mauborgne; C Plancher; F Mulot; J-P Delord; A Gonçalves; C Gavoille; C Dubot; N Isambert; M Campone; O Trédan; F Ricci; M Alt; D Loirat; M-P Sablin; X Paoletti; V Servois; C Le Tourneau
Journal:  Ann Oncol       Date:  2017-03-01       Impact factor: 32.976

5.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Authors:  Benjamin J Solomon; Tony Mok; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Shrividya Iyer; Arlene Reisman; Keith D Wilner; Jennifer Tursi; Fiona Blackhall
Journal:  N Engl J Med       Date:  2014-12-04       Impact factor: 91.245

6.  Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.

Authors:  Apostolia-Maria Tsimberidou; Nancy G Iskander; David S Hong; Jennifer J Wheler; Gerald S Falchook; Siqing Fu; Sarina Piha-Paul; Aung Naing; Filip Janku; Rajyalakshmi Luthra; Yang Ye; Sijin Wen; Donald Berry; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2012-09-10       Impact factor: 12.531

Review 7.  Characteristics of Exceptional or Super Responders to Cancer Drugs.

Authors:  Vinay Prasad; Andrae Vandross
Journal:  Mayo Clin Proc       Date:  2015-11-03       Impact factor: 7.616

8.  Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.

Authors:  Isaac Kinde; Chetan Bettegowda; Yuxuan Wang; Jian Wu; Nishant Agrawal; Ie-Ming Shih; Robert Kurman; Fanny Dao; Douglas A Levine; Robert Giuntoli; Richard Roden; James R Eshleman; Jesus Paula Carvalho; Suely Kazue Nagahashi Marie; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Luis A Diaz
Journal:  Sci Transl Med       Date:  2013-01-09       Impact factor: 17.956

9.  Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas.

Authors:  Yuxuan Wang; Simeon Springer; Carolyn L Mulvey; Natalie Silliman; Joy Schaefer; Mark Sausen; Nathan James; Eleni M Rettig; Theresa Guo; Curtis R Pickering; Justin A Bishop; Christine H Chung; Joseph A Califano; David W Eisele; Carole Fakhry; Christine G Gourin; Patrick K Ha; Hyunseok Kang; Ana Kiess; Wayne M Koch; Jeffrey N Myers; Harry Quon; Jeremy D Richmon; David Sidransky; Ralph P Tufano; William H Westra; Chetan Bettegowda; Luis A Diaz; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Nishant Agrawal
Journal:  Sci Transl Med       Date:  2015-06-24       Impact factor: 17.956

10.  Mutational landscape and significance across 12 major cancer types.

Authors:  Cyriac Kandoth; Michael D McLellan; Fabio Vandin; Kai Ye; Beifang Niu; Charles Lu; Mingchao Xie; Qunyuan Zhang; Joshua F McMichael; Matthew A Wyczalkowski; Mark D M Leiserson; Christopher A Miller; John S Welch; Matthew J Walter; Michael C Wendl; Timothy J Ley; Richard K Wilson; Benjamin J Raphael; Li Ding
Journal:  Nature       Date:  2013-10-17       Impact factor: 49.962
View more
  1 in total

1.  Paired tumor sequencing and germline testing in breast cancer management: An experience of a single academic center.

Authors:  Elizabeth Elliott; Virginia Speare; James Coggan; Carin Espenschied; Holly LaDuca; Amal F Yussuf; Kelly Burgess; Phillip Gray; Melody Cobleigh; Ruta Rao; Jeremy Patel; Timothy Kuzel; Lela E Buckingham; Lydia Usha
Journal:  Cancer Rep (Hoboken)       Date:  2020-09-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.